Johnson & Johnson stock
JNJNYSEHealthcareISIN US4781601046
75Score 75 out of 100, Strong
Price and trend
82 / 100
Price history
+46% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 70).
The price is at its 52-week high. Largest decline in 20 years: 35% (September 2008 to March 2009).
Chart figures for advanced users
- SMA 50$266.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$249.49
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$194.39
- The lowest closing price of the last twelve months.
- Resistance$283.52
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Johnson & Johnson belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $682.52B, is number 2 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $94.19B (up 6% year on year) and earnings of $26.8B (up 90.6%).
- For fiscal 2026, analysts expect on average revenue of $101.22B (up 7.5%) and adjusted earnings per share of $11.11 (up 2.9%).
Show more
- MEQIRI Score 75 out of 100 (Strong): rank 71 of 702 in Healthcare, median 53.
- The P/E is 43.1 (Drug Manufacturers (General) median 25.7, own median of recent years 22.4).
- Our model puts fair value at $181.98, with the price 56% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 56 years.Capital allocation 83
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 97
- High return on capitalReturn on invested capital 21.8% in fiscal 2025, Drug Manufacturers (General) median 13.4%.Profitability 85
Weaknesses
- Above fair valuePrice 56% above the fair value of $181.98.Valuation 16
- Richly valuedP/E 43.1, Drug Manufacturers (General) median 25.7, own median 22.4.Valuation 16
Its standout strengths are fundamentals and momentum, while growth and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- very large company
- calm price action
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $151.65 and expensive above $227.48 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $194.90 (cash-flow model) and $169.06 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $165.21, at 7.8% it would be $207.18.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 27 Sep 2026, revenue rose 7.8% on the twelve months before. Up to 2021 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 6.3% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating 27%, net 28%. Last 12 months: net 16%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 26 Jan 2027in 74 days
- Last reported
- 13 Oct 2026EPS reported $2.59 (expected $2.52)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $11.11−0.6%
- Revenue
- $101.22B0.0%
- Earnings per share
- $11.59−2.2%
- Revenue
- $107.76B−0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −3.7%The 2026 guidance was raised, with operational sales growth of 6.7% to 7.1% at a higher midpoint, adjusted operational EPS of $10.95 to $11.05, and an operating margin decline of 60 basis points versus 75 in July.
“Regarding operating margin, we now expect a decline of approximately 60 basis points This is an improvement from the 75-basis points decline reflected in our updated July guidance that included the impact of the Firefly Bio and Cell BioMedicines transactions, which had a unfavorable impact of 150 basis points.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $67.15M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Schmid TimothySale
2 Sept 2026, EVP, WW Chair, MedTech
- Shares
- 22,527
- Price
- $274.74
- Value
- $6.19M
- Taubert Jennifer LSale
17 Aug 2026, EVP, WWC. Innovative Medicine
- Shares
- 15,000
- Price
- $263.36
- Value
- $3.95M
- Duato JoaquinSale
13 Aug 2026, CEO and Chairman of the Board
- Shares
- 123,291
- Price
- $261.17
- Value
- $32.2M
Show 4 more
- Forminard ElizabethSale
6 Aug 2026, EVP, Chief Legal Officer
- Shares
- 15,918
- Price
- $257.00
- Value
- $4.09M
- Duato JoaquinSale
5 Aug 2026, CEO and Chairman of the Board
- Shares
- 48,480
- Price
- $258.15
- Value
- $12.52M
- Broadhurst VanessaSale
20 Jul 2026, EVP, Global Corp Affairs
- Shares
- 23,054
- Price
- $251.27
- Value
- $5.79M
- Wengel Kathryn ESale
11 Jun 2026, EVP, Chief TO and Risk Officer
- Shares
- 10,000
- Price
- $241.15
- Value
- $2.41M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Johnson & Johnson
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 75
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Eli LillyLLY $1.34T85
- AbbVieABBV $520.47B74
- Roche HoldingROP.SW $394.85B77
- MerckMRK $362.27B68
- NovartisNOVN.SW $304.26B75
- AstraZenecaAZN $285.95B73
- AmgenAMGN $252.64B76
- Gilead SciencesGILD $208.31B57
ETFs that hold Johnson & Johnson
Held by 141 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 9.86% | 0.15% | €3.29B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 9.84% | 0.12% | €1.39B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 9.80% | 0.15% | €599.59M |
Show 5 more
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 7.12% | 0.25% | €4.12B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 5.80% | 0.18% | €839.61M |
| iShares Edge MSCI USA Momentum Factor UCITS ETFQDVA | 4.97% | 0.20% | €529.83M |
| Xtrackers MSCI North America High Dividend Yield UCITS ETF 1CXDND | 4.67% | 0.39% | €266.63M |
| iShares Dow Jones Industrial Average UCITS ETF (DE)EXI3 | 3.14% | 0.51% | €322.26M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 28 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.